Table 1.

Novel agents in indolent lymphomas.

Drug class	Representative drugs	Targets
Alkylating agents	Bendamustine	DNA
Type I anti-CD20 monoclonal antibodies	Ofatumumab	CD20
Type II anti-CD20 monoclonal antibodies	Obinutuzumab	CD20
Anti-CD22 monoclonal antibodies	Epratuzumab	CD22
Anti-CD80 monoclonal antibodies	Galiximab	CD80
Immunoconjugated monoclonal antibodies	Inotuzumab Ozigamicin	CD22 and DNA
Bispecific antibodies	Blinatumumab	CD3 and CD19
Proteasome inhibitors	Bortezomib	Proteasome
	Carfilzomib
Signalling pathway inhibition	Temsirolimus	mTOR
mTOR inhibitors	Everolimus
PI3K inhibitors	CAL-101	PI3K
BTK inhibitors	PCI-32765	BTK
Bcl-2 inhibitors	AT-101	Bcl-2 family
	ABT-263
	Obatoclax
Immunomodulatory drugs	Lenalidomide	Microenvironment